

Chronic Hepatitis B (CHB) Market Valued at \$4.6+ Billion, Set for Rapid Growth Driven by Accelerated R&D Efforts

PORTLAND, OR, UNITED STATES,
December 2, 2024 /EINPresswire.com/
-- Overview of Chronic Hepatitis B

Chronic hepatitis B is a serious viral infection that leads to liver inflammation and can result in severe liver damage. The hepatitis B virus (HBV) primarily spreads through contaminated blood. Diagnosis involves several tests, including antibody tests, genotype tests, and viral load tests. Treatment options include antiviral drugs and immune modulators.



Chronic Hepatitis B (CHB) Market growth analysis

Request a sample report: <https://www.alliedmarketresearch.com/request-sample/A31523>

Key Market Drivers

- **Increased Blood Transfusion Rates:** The rise in blood transfusions necessitates mandatory hepatitis testing for blood banks, contributing to market growth.
- **Rising Infection Rates:** An estimated 296 million people were living with chronic hepatitis B as of 2019, with 1.5 million new infections annually, according to the World Health Organization (WHO).
- **Advancements in Treatment:** New product launches and approvals are enhancing treatment options for patients. For example, Gilead Sciences announced promising results for its entry inhibitor Hepcludex in treating chronic hepatitis delta virus infection.
- **Growing Diagnostic Centers:** The increase in diagnostic facilities and stringent regulations for blood donations help in early detection and treatment of hepatitis B.

Market Segmentation

The [chronic hepatitis B market](#) is segmented by:

- Drug Class:

- Antivirals: This segment dominated the market in 2021 and is expected to maintain its lead due to ongoing improvements in healthcare infrastructure.
- Immune Modulators: Anticipated to grow significantly due to increased research and development activities.
- Gender:
 - Males: This segment accounted for a larger market share due to higher prevalence rates among men.
 - Females: Expected growth as more female healthcare workers enter the field and healthcare spending increases.
- Distribution Channel:
 - Drug Stores & Retail Pharmacies: This segment led the market in 2021, supported by government initiatives to enhance healthcare infrastructure.
 - Online Providers: Anticipated significant growth driven by the increasing number of online pharmacies catering to a growing geriatric population.
- Region:
 - North America: Held the largest market share in 2021, bolstered by a robust healthcare system and high incidence of chronic diseases.
 - Asia-Pacific: Projected to witness substantial growth due to rising infection rates and improving healthcare infrastructure.

Key Players

The competitive landscape includes major players such as:

- Gilead Sciences, Inc.
- Biocon Inc.
- Cipla Limited
- Novartis AG
- Sun Pharmaceutical Industries Limited
- Teva Pharmaceuticals
- Viatris Inc.

Conclusion

The chronic hepatitis B market is poised for steady growth over the coming years, driven by increased awareness, improved treatment options, and supportive healthcare policies. As research continues to advance, new therapies are likely to emerge, further enhancing patient outcomes and expanding market opportunities. This dynamic environment presents both challenges and opportunities for stakeholders involved in the management and treatment of chronic hepatitis B.

□□□□□□ □□□□□□ □□□□□□: <https://www.alliedmarketresearch.com/purchase-enquiry/A31523>

David Correa

Allied Market Research

+1 800-792-5285

[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/765450050>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.